LONNEL COATS
CIK 1612528 · Chief Executive Officer · last filed 2026-06-10
LONNEL COATS is a Chief Executive Officer who has filed 55 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for RLAY, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$1.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.78M
4
55
-$1.59M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RLAY | Director | — | $19.94 | — | $0 | 2 | 2026-06-10 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 5 | 2025-07-28 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 0 | $129.46 | $0 | -$2.69M | 15 | 2025-07-21 |
| LXRX | Chief Executive Officer | 1,159,439 | $2.40 | $2.78M | $1.11M | 30 | 2024-02-29 |
Recent Filings
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-10 | RLAY | Grant (A) | — | $0 | EDGAR |
| 2025-11-06 | RLAY | Grant (A) | — | $0 | EDGAR |
| 2025-07-28 | Verve Therapeutics, Inc. (VERV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-07-21 | Blueprint Medicines Corp (BPMC) Delisted | Disp (D) | −6,144 | $0 | EDGAR |
| 2025-06-24 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +3,902 | $49.99M | EDGAR |
| 2025-06-06 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-11-22 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −11,012 | -$1.25M | EDGAR |
| 2024-11-21 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −9,824 | -$931.4K | EDGAR |
| 2024-11-20 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −10,000 | -$946.0K | EDGAR |
| 2024-08-15 | LXRX | Notice (144) | −300,000 | -$480.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.